INVA vs ONC: fair value comparison
Innoviva, Inc. and BeOne Medicines AG · Updated 2026-10-19
ONC is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, INVA currently ranks higher by quality score.
| INVA | ONC | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $20.78 | $369.06 |
| 12-month range | $17.57–$24.24 | $260.27–$377.47 |
| Rank by discount to fair value | #43 of 108 Healthcare | — |
| Rank by quality score | #4 of 301 Healthcare | #6 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Uptrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: INVA fair value analysis · ONC fair value analysis